The class of 2027 was seated at the Alice Tully Hall at the Lincoln Center for the Performing Arts on Tuesday, September 12, waiting to be coated in the White Coat Ceremony, which marks the start of their medical education. Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, came up on stage and addressed the audience. He spoke about his own time in medical school.
Dennis Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, stressing the importance of a diverse student body at the White Coat Ceremony.
“Back then, medicine lacked so many of the tools we rely upon today,” Dr. Charney said. There was no sophisticated imaging equipment, nor things like DNA sequencing, but the medical field did its best to heal patients. “The world was a different place in 1973,” Dr. Charney said.
Medical science has made many breakthroughs—with Mount Sinai having played a significant role—and it faces exciting new chapters ahead. Some of these, Dr. Charney said, include integration of artificial intelligence and advanced genomics, allowing for better targeted interventions, and perhaps even for once-hard-to-treat cancers to become manageable chronic diseases. That is why the Health System has launched the Mount Sinai Million Health Discoveries Program—to usher in a new era of personalized medicine, he added.
And while science improves, so too must the field for those who work in it, and for whom it serves. Dr. Charney then pulled up a picture of himself in his class at Penn State College of Medicine. “Of 82 students, we had just 12 women and only four people of color,” Dr. Charney said. Then he showed a picture of the 120 students who comprised the cohort present in the hall. “The world has clearly changed for the better—your class is more than 50 percent women and 30 percent people of color,” he noted.
Of this year’s entering class, 53 percent are women, and 28 percent are from backgrounds considered underrepresented in medicine, including racial and economic groups. In comparison with the class that graduated 50 years ago, while race and ethnicity data was not collected back then, the class of 1977 at Icahn Mount Sinai had 24 percent women out of 91 students.
“In spite of the recent Supreme Court decision on college admissions, future classes here at Icahn Mount Sinai will continue to be highly diverse,” Dr. Charney said. “Icahn Mount Sinai will not stand down from our strong commitment to diversity, equity, and inclusion. And we will do this legally, under the law.”
The message of diversity resonated with the incoming students. “From my experience, having a diverse body is the only way to go forward as a school, as it then provides a diversity of opinion,” said Nathan Ji, Class of 2027.
“It’s very important to have representations of patients who look like them, from the physicians who treat them,” said Rico Pesce, Class of 2027. “I’m super proud to be part of a school that places importance on this.”
Click to read more about some of the students from the Class of 2027 and the journey they have taken.
Nathan Ji
What drew you to Icahn Mount Sinai?
I first came to hear of Icahn Mount Sinai through friends at Johns Hopkins, where I went for undergrad, who had gotten in through Mount Sinai’s unique FlexMed program. As someone still far removed from the medical school application process back then, I casually asked them why they had elected to commit to Mount Sinai. Their responses varied, of course, but one central theme stuck out: the commitment of the medical school to serving the community.
I remained curious but mildly doubtful of the claim, until I ended up visiting the medical school during Second Visit Weekend this past spring. It was then that I realized the distinct difference between an “East Harlem medical campus” and a “medical campus located in East Harlem.” Icahn Mount Sinai embodied the spirit of the former.
From the several medical student-run community clinics to anti-racism initiatives led by faculty physicians, it was clear that Mount Sinai cared about the community. There is still much more work to be done, of course, but Mount Sinai’s self-awareness of its responsibilities to the people in its vicinity is seldom found among its peers.
It is no coincidence that such a socially conscious school would have such a positive impact on mental health and wellness among its student body. I may not have the same support system from home, but, no matter what background you come from, there will be support for you here, I guarantee it.
What made you decide to enter medicine?
Growing up, I always thought I would become a scientist. Such was the ambitions of a lonely boy growing up in China, whose parents were thousands of kilometers away working in exciting research laboratories to change the world. I never saw myself as being sociable enough to be the “physician-type,” given my introverted personality and upbringing as an only child and perpetual new kid in school.
But that all began to change in 2015 when I returned to China with my parents for the first time since we had left when I was still a child. A sudden trip in the middle of October was no leisurely vacation; we arrived just after midnight at the ICU where my grandfather lay on his deathbed. It was there that I saw the uniquely humanistic challenges that medical professionals dealt with on a regular basis.
We, the family, consulted with the attending physicians on the ethics of pulling the plug to lay my grandfather to rest. All the while around us in the dead of night lay several other elderly patients, each with their own families and individual stories. I realized then that physicians weren’t just sociable professionals who leveraged knowledge of science to help people. Above all, they were care providers who embarked on distinctive humanistic journeys with each of their patients.
The rest, as they say, was history. Sure, there were still seven more years of high school, research internships, undergraduate classes, volunteering and exposure to medical settings, shadowing physicians, tutoring students in underprivileged backgrounds, and a million more exciting adventures along the way. But as I embark on my first medical school classes this fall, I distinctively remember that dark desolate night in Shanghai, as the spark that lit my passion for medicine.
What’s an interesting fact about you?
During orientation I would ask my classmates to guess how many schools I have attended before Icahn Mount Sinai. Most guessed four or five, as is the common pathway—elementary, middle, high schools, and university. Others guessed between six and eight. Yet all would be surprised at my eventual answer of eleven.
I lived in Shanghai, where I was born, for a whopping four months, before I was sent to live with my grandparents in Tianjin, near Beijing. Thus, I had no memories of being with my parents until we reunited when I immigrated to the United States and arrived in Chicago at the age of eight. Two years later, we would move to Salt Lake City, and then to Tampa six years after that. And then I would go to Johns Hopkins University just two years afterward.
Looking back, what really stood out about my unique upbringing is the diversity of culture that I experienced. There were so many ways of living, so many unique compositions of heritage among the people who I called my friends and neighbors throughout the various locations. That is why I want to pursue medicine in a melting pot like New York, where I can encounter people, patients, and colleagues from all walks of life.
Michael Lemonick
What drew you to Icahn Mount Sinai?
I was initially drawn to Mount Sinai as it is one of the most veteran-friendly medical schools in the nation. I am a veteran of the U.S. Navy, having served eight years on active duty as a surface warfare officer, and Mount Sinai’s institutional partnership program with the military allowed me to apply directly to medical school while still serving on active duty.
In fact, I actually completed my application while deployed on an Arleigh Burke-class destroyer during the height of the pandemic. Without Mount Sinai’s veteran-friendly policies, I am not sure that I ever would have been able to realize my dream of becoming a doctor, and for that I feel enormously indebted to Mount Sinai. I am also drawn to Mount Sinai’s emphasis on equitable care and leadership in addition to its standards of scientific excellence.
What made you decide to enter medicine?
As a child, I had the opportunity to witness physicians treat my family and literally save their lives: my mother and both of my grandmothers suffered from breast cancer, while my father and paternal grandfather both suffered from prostate cancer. My sister is a type 1 diabetic who, with the help of spectacular physicians, has worked hard since her diagnosis at six years old to manage her disease.
As an athlete, I suffered broken bones and other sports-related injuries throughout my childhood, teenage, and college years, and each time I was met by competent, confident, and compassionate physicians who were always able to quell my anxieties.
Inspired by those who treated my family members and me in times of need, I knew that I always wanted to become a dependable physician; one who can deliver excellent care while imbuing patients with the confidence and strength to overcome their ailments. With this experience, and with my love of science, a career in medicine always seemed an obvious choice for me.
What’s an interesting fact about you?
I am a 2015 graduate of the U.S. Naval Academy, and I subsequently served on active duty for eight years. From 2018-2021, I was stationed in Rota, Spain, onboard a destroyer, where I served as the lead navigator on three of five deployments. I was the first navigator to make a port call in the Faroe Islands of Denmark, and I was part of a group of ships to navigate along the north coast of Russia in the Barents Sea for the first time since the Cold War.
As an athlete, I played on the varsity soccer team at the Naval Academy. I am still passionate about soccer and athletics in general, especially from the perspective of using sports as a vehicle for developing leadership, toughness, and the will to win.
I am an aspiring writer and am currently working on a memoir of my time at sea in the Navy. Finally, I lived in France for two years as an ensign in the Navy, where I completed a bilingual master’s degree in international affairs at the Paris Institute of Political Studies. I work to maintain my level of French and enjoy learning about various aspects of French culture, including its cuisine, art, and history.
Boluwatito Oladeinde
What drew you to Icahn Mount Sinai?
Its unique position on the borders of the richest and poorest ZIP codes in New York City would expose me to a variety of patient cases and interactions.
I also appreciate that it is in the northeast United States, where I have my adopted family and friends, which would be integral for me to get through the mental and physical rigors of medical school. New York City was also appealing to me as I am interested in fashion and art—what better place to experience and participate in this than in NYC?
What made you decide to enter medicine?
My choice stems from my childhood experiences growing up in Nigeria, and as an uninsured adult in the United States. My father constantly struggled with his health growing up, and between the ages of 12 and 14, he underwent four separate neurosurgery procedures in India and in the United States. This was scary because, as a family, we never knew how these surgeries were going to pan out. This was the first thing that prompted my desire for a career in medicine.
Over the course of my 18 years in Nigeria, I also witnessed the poor health care system in the country and suffered a loss due to an avoidable occurrence in the system. This further strengthened my desire to provide quality health care to my home country, and other disadvantaged communities around me.
What’s an interesting fact about you?
I was born and raised in Lagos, Nigeria, and migrated by myself to the United States at the age of 18 for college at Howard University in Washington, D.C. Looking back, it is astounding how I have successfully navigated being in a new country, culture, and system without the presence of my immediate family, who all live in Nigeria. My parents made the trip to the United States for my White Coat Ceremony and were very proud of me for being the first person in my family to go to college and medical school.
Rico Pesce
What drew you to Icahn Mount Sinai?
After the military, I did my undergraduate studies at Columbia University. There, I met a person doing post-baccalaureate studies, who did the Institutional Partnership program with Mount Sinai. When he started at Mount Sinai, he introduced me to its culture and the school.
The school’s mission and focus on developing cutting-edge technologies aligned well with my personal goals. Furthermore, every person I had talked to had nothing but positive things to say. I also love being in New York City, and Mount Sinai is certainly one of the most welcoming institutions I’ve come across.
What made you decide to enter medicine?
My interest in medicine began in high school, where for a biology class, we went to a cadaver lab. I became fascinated with the anatomy and science of the human body. Later on, I became a certified nurse assistant and worked in a dementia facility, and decided to go to school in a community college to further my career. However, I wasn’t thriving academically, left community college, and joined the military.
I became a special operations combat medic for the 75th Ranger Regiment. I ended up staying in the military for seven years, where I had been platoon medic, senior medic, battalion clinic manager, and completed five deployments in Afghanistan.
I have treated patients at their most vulnerable—even their last moments on earth—and there is not a more meaningful way to spend my time in this world than to be part of a team to help improve and prolong people’s human experience. Once I saw the impact on my patients’ lives as a medic, it drew me to want to learn more about medicine and be able to provide care in a definitive way. I then decided it was time to separate from the military to pursue my goal of becoming a physician.
Throughout my education and experience providing care on the front lines of the pandemic, I realized that the responsibilities of a physician went well beyond the one-on-one contact with patients. Physicians have such immense responsibility to their patients, and to society at a larger scale, and I have updated the vision for my future to include medical device innovation. It has been a long journey, but I am proud to continue down the path of being in medicine and advancing the field.
What’s an interesting fact about you?
I am a proud member of the gay community and my fiancé, Zach Thomas, is a third-year medical student at a nearby university. It is amazing to have a significant other who is also studying medicine because he understands what I am going through, and we can share our passion for medicine for many years to come.
The circular diagram displays which nearby gene or genes are connected to new variants linked with PSA levels. Kachuri, L., Hoffmann, T.J., Jiang, Y. et al.,Nature Medicine.
Prostate-specific antigen (PSA) screening has long been the gold standard for detecting prostate cancer at an early stage, aiming to improve treatment outcomes and increase survival rates.
But the screening tool is not without its controversies. PSA levels can be affected by various factors, resulting in false positives or negatives. This test may miss some cancers while detecting others that might not actually be clinically significant.
Therefore, there has been a growing interest in the field to find ways to enhance its effectiveness.
The answer might lie in every man’s genes.
In the June 1 online issue of Nature Medicine, a team of researchers from the Icahn School of Medicine at Mount Sinai and collaborators revealed that tailoring prostate cancer screening to individuals, in which PSA is adjusted for genetic factors, could offer a more viable approach to enhancing screening.
“While utilizing blood PSA levels for prostate cancer screening remains contentious due to issues like detecting cancer in men with low PSA and missing it in those with slightly elevated PSA, our multicenter study aimed to improve this approach by accounting for individual genetic variations in PSA levels,” says Robert J. Klein, PhD, Professor, Genetics and Genomic Sciences and a co-author of the paper.
Drawing from Dr. Klein’s earlier research highlighting the impact of individual genetics on PSA levels, this study aimed to determine whether adjusting for these genetic factors could enhance the accuracy of the screening tool.
“The goal is for this to pave the way for using genetically tailored PSA levels for prostate cancer screening, instead of using raw PSA levels,” says Robert J. Klein, PhD.
Using data from several cohorts of healthy men of diverse ancestries, the researchers measured PSA and genetic variants. Computational analyses linked each variant to PSA levels, and an algorithm constructed a genetic model for predicting PSA levels. The study assessed the effectiveness of PSA, either adjusted or not adjusted using this score, in predicting prostate cancer presence upon biopsy.
The researchers found that the score could predict nearly 10 percent of variation in PSA levels. However, it demonstrated more effectiveness in men of European descent than of East Asian or African heritage. Upon applying their scoring method to a dataset comprising men with and without confirmed prostate cancer through biopsy, the researchers estimated that about 30 percent of the men could have been spared from undergoing unnecessary biopsies.
“Our study shows how genetic variants can predict PSA levels and explores using this prediction in patient care. The goal is for this to pave the way for using genetically tailored PSA levels for prostate cancer screening, instead of using raw PSA levels,” says Dr. Klein.
Next, the researchers plan to perform a broader analysis involving more individuals of diverse ancestries, including through the BioMe® biobank at Mount Sinai. This step aims to confirm the applicability of the score across different populations.
Dr. Klein and his team are also exploring, as part of a separate undertaking, whether genetics could be used to better predict individuals at risk for prostate cancers that are potentially life-threatening.
Residents took a community health tour to meet local community leaders and visit the East Harlem Neighborhood Action Center, the East Harlem Asthma Center of Excellence, and the NYCHA Jefferson Houses. From left: Riana Jumamil, MD; Kierstin Luber, DO; Megha Srivastava, MD; and Betty Kolod, MD, Associate Residency Program Director.
The Icahn School of Medicine at Mount Sinai General Preventive Medicine Residency Program has won a prestigious federal grant designed to reduce social inequities in health care through enhanced resident training and expanded public health intervention.
Under terms of the four-year award, the program’s six residents take an intensive summer course in health equity. Residents learn about health literacy, communication, and data analysis skills to address health disparities. They will apply these skills during a longitudinal population health rotation at several Federally Qualified Health Centers (FQHC) throughout New York City, which specialize in homelessness, HIV, and other issues.
“We’re excited for a deeper level of community engagement with these health centers and hope some residents continue their careers at FQHCs,” said Kristin Oliver, MD, MHS, General Preventive Medicine Residency Program Director and Associate Professor, Environmental Medicine and Public Health, Pediatrics, and Medical Education.
All of the program’s residents train in a broad range of topics including population health, quality improvement, lifestyle medicine, cancer prevention and tobacco cessation. Mount Sinai’s program is known for encouraging residents to customize their education according to individual passions. Each resident chooses a particular focus, such research or advocacy.
Recent program graduates include a resident who focused on primary care services for LGBTQ patients and worked with infectious disease doctors at the James J. Peters VA Medical Center in the Bronx to establish an HIV infection prevention program at the Center. Another graduate focused on research to address underrepresentation of the Black, Indigenous and People of Color community in cancer clinical trials.
Residents rotate through the New York City Department of Health and Mental Hygiene, working on issues such as COVID-19 response, measles outbreaks, and reducing pregnancy-associated mortality among Black women. Shifting public policy is also a focus of the residency program. All residents learn to write op-eds or give oral testimony as part of their training.
“Our specialty is so broad, which is what makes our residency so fun and fabulous,” said Dr. Oliver. “Each resident has a different passion, and we help identify mentors and bring their skills to the next level to make a big impact. Everyone brings in something different, then we all gain from it.”
Laura Sirbu, MD, the program’s co-chief resident, is studying how “upstream” factors such as barriers to health care access can be addressed to allow people in nearby communities to live healthier lives.
Dr. Sirbu said she is excited about the grant and that she is enjoying the training. “It’s great to secure extra support,” she said. “Mount Sinai’s program strength is its support of residents to go down different paths, allowing them to choose from a variety of project types and research topics.”
Residents can apply to the program, which is being renamed the Icahn School of Medicine at Mount Sinai Public Health and General Preventive Medicine Residency Program, after completing one year of a clinical residency or after completing a full clinical residency.
During the two-year program, residents earn a Master’s Degree in Public Health. The program has longstanding ties with East Harlem’s nonprofit groups, which enable the program to build relationships and make a bigger impact.
“It’s not just one patient at a time, it’s the entire community,” said Dr. Oliver.
At the Third State Central Hospital in Ulaanbaatar are, left to right, Senzaaya, a scrub nurse, Saadi Ghatan, MD, Ariel Stock, MD, a neurosurgical resident at Montefiore Hospital, and Sloane Sheldon, PhD.
On Friday, May 12, Saadi Ghatan, MD, Chair of Neurosurgery at Mount Sinai West and Mount Sinai Morningside, and Sloane Sheldon, PhD, a clinical neuropsychologist in the Mount Sinai Epilepsy Program, boarded a ten-hour flight from New York to Istanbul. From there, they hopped on another ten-hour flight to Ulaanbaatar, the vibrant capital of Mongolia.
Thanks to support from the Virtue Foundation, a non-profit organization committed to transforming lives through health care, education, and empowerment initiatives, they spent the next two weeks providing medical services to epilepsy patients alongside a team of local doctors and volunteers representing a variety of advanced surgical and medical specialties.
On their first day in Ulaanbaatar, they arrived at the hospital at 8:30 am and met patients until midnight. Local neurosurgeon, Abai Siyez, MD, and epileptologist Bayarmaa Dondov, MD, had selected almost 150 patients for them to evaluate. In Mongolia, the options for epilepsy medications and pre-surgical evaluations are limited. Most patients can only get MRIs, which can be unreliable, and routine outpatient electroencephalograms (EEGs). With limited access to medication that could otherwise help, surgery becomes all the more important and sought after by patients and families.
Dr. Ghatan has a deep connection to Mongolia, as this marked his third visit to the country. His journey began in 2019 when he volunteered to teach local neurosurgeons advanced techniques and provide essential surgical procedures in pediatric neurosurgery. It was during this initial trip that he met Dr. Siyez at Third State Central Hospital in Ulaanbaatar. Dr. Siyez is the grandson of the man known as the founder of Mongolian neurosurgery. Dr. Ghatan introduced the team to neuroendoscopic surgery during that first volunteer trip. At the time, Third State Central Hospital lacked much of the surgical equipment required for these advanced surgical procedures.
Dedicated to his work and eager to advance in Neurosurgery in Mongolia, Dr. Siyez applied for funding from the Asian Development Bank to update the medical facilities at his hospital. Thanks to the grant funding he received, he successfully replaced his hospital’s outdated equipment and applied Dr. Ghatan’s teaching to treat new patients with state-of-the art equipment. One of Dr. Ghatan’s key aims in Mongolia is to continue collaborating with Dr. Siyez and sharing knowledge and techniques with local surgeons, allowing them to perform surgeries independently in the future.
Abai Siyez, MD, center, at the Third State Central Hospital in Ulaanbaatar with his team, performing a left temporal lobectomy surgery. Saadi Ghatan, MD, is shown on the right.
Dr. Ghatan and Dr. Sheldon screened patients in the first three days of their visit. Over the following week and a half, Dr. Ghatan, Dr. Siyez, and the surgical team successfully performed 21 epilepsy surgeries—an extraordinary number—ranging from temporal lobectomy to frontal and parieto-occipital disconnections, awake craniotomy, and more neuroendoscopy. As many of the locals are not fluent in English, Dr. Siyez plays an important role in making sure patients understand Dr. Ghatan’s communication, both culturally and medically.
Dr. Sheldon performed pre-surgical neuropsychological evaluations on patients. She administered patients with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a test used for evaluating cognitive functioning. Understanding the limitations of the test, which is designed for an American population, she worked closely with an interpreter who helped ensure the accuracy and the cultural appropriateness of the testing materials. This was her first medical trip to Mongolia, and she was impressed by how open and eager the locals were to receive a neuropsychological evaluation. In addition to seeing patients, she also delivered a lecture on neuropsychology with neurologists and psychiatrists in the audience, which was a very rewarding experience.
For Dr. Ghatan, the trip was particularly meaningful because he was able to see and interact with the patients he had operated on during his previous trips.
“Seeing these lovely people living better lives with much more independence is gratifying,” he says.
Follow up, of course, is critical, and after these visits, Dr. Siyez shares regular updates about the patients they saw. They are planning to organize a monthly/quarterly case management conference to streamline information sharing.
With so much demand for these surgical procedures, and a successful track record of working with and training local doctors like Dr. Siyez, these two Mount Sinai ambassadors hope this continued connection will motivate the hospital in Mongolia to invest in more resources and focus on building better collaborations between neurologists, neuropsychologists, and neurosurgeons.
Dr. Sheldon and Dr. Ghatan are both looking forward making another volunteer trip to continue to improve the lives of people living with epilepsy and transfer knowledge to doctors in Mongolia. They were struck by how open and optimistic their patients were.
“The patients and their families were strong, resilient, and extraordinarily grateful,” says Dr. Sheldon. “I was so impressed by how open the locals are to take extra measures to ensure that they get the treatment they need and deserve.”
Steven Wallace, an Outreach and Education Coordinator for the World Trade Center (WTC) Health Program at Mount Sinai, was celebrated by the Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, for recently receiving the Steven McDonald Forged by the Sea Award.
This recognition was given by the New York Police Department and the United States Navy Association and presented by Police Commissioner Keechant Sewell and the family of late Detective McDonald.
According to Julia Nicolaou Burns, Administrative Director, Selikoff Centers for Occupational Health, Steven’s role revolves around raising awareness about the medical and mental health monitoring and treatment services Mount Sinai offers to 9/11 workers and volunteers.
“As a 9/11 responder himself,” she says, “Steven goes above and beyond to make sure anyone affected by 9/11 knows about the services and benefits available through the WTC Health Program. He spends countless hours working in the field, connecting with responders, law enforcement unions, and other stakeholders. He is a true definition of empathy, compassion, teamwork, and commitment. We are incredibly proud to have Steven as part of our team, and we are so honored that the NYPD recognized Steven for his incredible work.”
Steven points out that many who people are eligible for free medical benefits through the WTC Health Program may not be aware. His mission is to get them the free and expert care they deserve.
Steven is humble at being honored, and shares his honor with the team and the people he serves.
“The 9/11 community and Mount Sinai’s Clinical Center of Excellence are my family, and together, we have saved lives. There is no greater gift to give of one’s self than the gift of saving a life.“
The WTC Health Program was established by the James Zadroga 9/11 Health and Compensation Act of 2010 and is administered by the National Institute for Occupational Health and Safety. It provides free medical monitoring, treatment, mental health services, and benefits counseling for 9/11 responders and volunteers. Mount Sinai is home to the largest WTC Health Program Clinical Center of Excellence in the region. To learn more, visit the site, email wtchealthprogram@mountsinai.org, or call 888-702-0630.
Respiratory viruses, such as influenza and respiratory syncytial virus (RSV), tend to pick up during fall. On top of that, COVID-19 is still circulating, with cases increasing in recent weeks. To fight off what some are calling a “tripledemic” of all three viruses, state and federal health officials are urging people to protect themselves with vaccines.
In an interview, Bernard Camins, MD, Professor of Medicine (Infectious Diseases), and Jennifer Duchon, MD, Associate Professor of Pediatrics (Newborn Medicine), at the Icahn School of Medicine at Mount Sinai, provided additional background about vaccines that will be available this fall.
COVID-19
COVID-19 cases and hospitalizations are not as high as they used to be at the height of the pandemic. But hospitalization counts—which are still being reported—have risen in recent weeks.
“We can’t just forget about COVID-19 yet,” says Dr. Camins.
On Monday, September 11, the U.S. Food and Drug Administration (FDA) cleared updated COVID-19 vaccines for use that are formulated to more closely target currently circulating variants. The FDA approved the Pfizer and Moderna vaccines—known as “messenger RNA” or “mRNA” vaccines for the type of technology they use—for people 12 and over. It granted emergency use authorization to the same vaccines for people six months to 11 years old.
On Tuesday, September 12, a panel of the Centers for Disease Control and Prevention (CDC) voted to recommend the updated vaccines for everyone six months and older. The CDC recommended that most people get one dose of the new vaccine, at least two months after their most recent vaccine dose. People who are immunocompromised, and parents of young children, should consult their doctor for recommended dosing.
Dr. Camins said the updated COVID-19 shots from Pfizer and Moderna are monovalent vaccines—meaning they are designed to target a single variant of SARS-CoV-2, the virus that causes COVID-19—but are expected to provide broad protection against the other currently dominant circulating variants of SARS-CoV-2 as well. He said patients should check with their primary care doctor’s office or local pharmacy to find out how and when they can get the new vaccines.
“Based on past developments, it could be within a matter of days for the shots to be available to the public once the recommendation is made,” says Dr. Camins.
The number of people hospitalized due to COVID-19 has been rising steadily in the city in August. Source: NYC Department of Health and Mental Hygiene
RSV
The respiratory syncytial virus commonly causes mild, cold-like symptoms in most healthy adults and goes away after a few days. However, for infants and older adults with pre-existing heart disease or lung disease, RSV can cause severe disease. This year, new vaccines are available for these vulnerable groups.
“RSV is ubiquitous,” says Dr. Duchon. “You can try to prevent it, but even then options are limited. While parents can practice good hand hygiene and stay away from other sick people, babies often have siblings who go to school or go to daycare.”
Most of the deaths or severe disease—typically lower-respiratory-tract disease—from RSV occur in infants ages 0 to 6 months, says Dr. Duchon.
In July, the FDA approved Beyfortus™ (nirsevimab-alip), marketed by Sanofi in the United States, for use in infants entering their first RSV season and up to 24 months of age for those in vulnerable groups. In August, the FDA approved Abrysvo™, from Pfizer, as a maternal vaccine to protect infants from birth through six months of age. Beyfortus is administered directly to infants after they are born, while Abrysvo is given to mothers at 32 weeks through 36 weeks of gestation.
ACIP has recommended that Beyfortus be given to all infants younger than 8 months born during—or entering—their first RSV season, typically fall through spring. For children 8 to 19 months who are at increased risk of severe RSV disease, such as those who are immunocompromised, a second dose is recommended.
Abrysvo has yet to receive ACIP recommendation, though news reports have stated that meeting could likely occur in September.
~1-3%
of children under 12 months of age in the U.S. are hospitalized each year due to RSV
~60,000-120,000 hospitalizations and ~6,000-10,000 deaths
among adults 65 years of age and older are due to RSV
Source: CDC
It is possible that the ACIP could recommend Abrysvo on top of Beyfortus. “We are hoping that the infant vaccine will help prevent severe disease, and that the maternal vaccine will add an additional layer of protection,” says Dr. Duchon. However, she notes that given how the clinical trials were set up, the expert panel will likely examine the data closely and deliberate on the messaging.
“This could be a shared decision-making situation between a mother and her doctor,” Dr. Duchon adds.
For older adults, the FDA approved Arexvy™ as a vaccine for people ages 60 and older, in May. “Particularly for people with heart or lung disease, RSV can exacerbate their conditions,” says Dr. Camins.
Older people in that vulnerable group should speak with their health provider on whether they should take the vaccine, especially as RSV season approaches, says Dr. Camins.
Influenza
The influenza virus season from fall 2022 to spring 2023 was marked by an early peak in November and December last year, according to the CDC. When the 2023-2024 flu season will peak is hard to pinpoint, but the CDC issued a recommendation in August for people to receive their flu shots in September or October.
“We are starting to see some influenza A cases here in our health system, which has a connection to how influenza A and B trends might play out through fall and winter,” says Dr. Camins. It is not a prediction of an early or bad flu season by any means, but he recommends that unless contraindicated, everyone older than six months of age take the flu shot.
The annual flu vaccine has been updated with a new formula, as is common, to target strains most likely to circulate this season. Anyone six months and older is recommended to receive it, according to the CDC.
“Even if you’re not at high risk for complications from the flu, getting the vaccine may prevent you from getting sick, or even if you do get sick, your symptoms will be milder if you take the shot than if you didn’t,” says Dr. Camins. “Everyone should be getting the flu vaccine.”
